The case for replacing live oral polio vaccine with inactivated vaccine in the Americas

JA Alfaro-Murillo, ML Ávila-Agüero, MC Fitzpatrick… - The Lancet, 2020 - thelancet.com
Before the development of the inactivated poliovirus vaccine (IPV) and live oral poliovirus
vaccine (OPV), sporadic outbreaks of poliomyelitis were reported to cause as many as 18 …

On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine

X Peng, X Hu, MA Salazar - The Lancet, 2018 - thelancet.com
Owing to the concerted efforts of countries worldwide, the incidence of paralytic poliomyelitis
due to wild poliovirus infection has been reduced to its lowest on record. Wild poliovirus type …

Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use

M Hill, AS Bandyopadhyay, AJ Pollard - The Lancet, 2022 - thelancet.com
Comment 714 www. thelancet. com Vol 400 September 3, 2022 risk of vaccine-associated
paralytic poliomyelitis caused by Sabin 2. 6 Although most countries eliminated Sabinlike …

Overcoming challenges en route to polio eradication

A O'Leary - The Lancet, 2022 - thelancet.com
Contrary to claims by T Jacob John and Dhanya Dharmapalan, 1 research demonstrates
that poliovirus transmission predominantly follows the oral-faecal route, 2 particularly in …

Halting vaccine-derived poliovirus circulation: the novel type 2 oral vaccine might not be enough

TG Nyenswah, JL Schue - The Lancet Global Health, 2023 - thelancet.com
Polio eradication remains elusive, and its progress has been hampered by the COVID-19
pandemic. 1 Wild-type polioviruses are endemic in two countries (Afghanistan and …

First Africa-based clinical trial for novel type 2 oral poliovirus vaccine

LV Cooper, IM Blake - The Lancet, 2024 - thelancet.com
The Global Polio Eradication Initiative owes much of its success in vastly reducing wild
poliovirus transmission globally to the use of live-attenuated Sabin oral poliovirus vaccine …

What threat from persistent vaccine-related poliovirus?

C MacLennan, J MacLennan - The Lancet, 2005 - thelancet.com
One of the outstanding scientific “endgame” questions for poliomyelitis eradication is how
long vaccine-related polioviruses will circulate after cessation of use of oral poliovirus …

Protective efficacy of a monovalent oral type 1 poliovirus vaccine

J Puliyel, C Sathyamala, D Banerji - Lancet, 2007 - thelancet.com
The article describes how the international oversight body on polio eradication
recommended the rapid development, licensing, and introduction of a new monovalent type …

[引用][C] Poliomyelitis eradication: another step forward

NW Crawford, JP Buttery - The Lancet, 2010 - thelancet.com
In The Lancet today, Roland Sutter and colleagues1 provide randomised data for a new
combination bivalent type 1 and 3 oral poliovirus vaccine (bOPV) in India. This vaccine will …

[HTML][HTML] Ending use of oral poliovirus vaccine—a difficult move in the polio endgame

MA Pallansch - New England Journal of Medicine, 2018 - Mass Medical Soc
Ending Use of Oral Poliovirus Vaccine The global health community has taken the first step
toward eliminating use of oral poliovirus vaccine: switching from trivalent to bivalent vaccine …